Digital Engagement and Predictors of Semaglutide Persistence and Weight Loss in Severe Obesity: 48-Week Observational Study
Journal of Medical Internet Research · 26.08.2026 · 28 · e80119-e80119
DOI: 10.2196/80119 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Medical Internet Research, online erschienen am 26.08.2026. Verfasst von Sarah Tournayre und 12 weiteren Autor:innen. Beteiligte Einrichtung: Nutrition-Diabetes Department, Montpellier University Hospital, Centre Hospitalier Universitaire de Montpellier, 191 Avenue Du Doyen Gaston Giraud, M…. Hauptthemen laut MEDLINE: Weight Loss, Glucagon-Like Peptides, Obesity, Morbid, Anti-Obesity Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Real-world persistence with antiobesity pharmacotherapy is suboptimal: only 32% to 50% of patients persist with glucagon-like peptide-1 receptor agonists at 12 months, and fewer than 15% reach the 2.4 mg/week target dose. Digital platforms may support engagement, but their role remains poorly characterized.
Objective
This study aimed to evaluate whether baseline engagement with a structured digital assessment platform (Aviitam ) predicts 48-week persistence and mediates weight-loss outcomes in adults with severe obesity initiating semaglutide 2.4 mg/week and to identify clinical and behavioral predictors of pharmacological response.
Methods
In this prospective 48-week single-center observational cohort, all consecutive adults (≥18 y) with a BMI ≥40 kg/m² initiating semaglutide 2.4 mg/week through the French early-access program were enrolled. Baseline engagement with the Aviitam digital assessment platform was operationalized as a 3-level ordinal variable (never used, partial use, and full completion of validated questionnaires), reflecting the patient’s responses to a nonenforced preclinical request. The primary outcome was 48-week persistence; secondary outcomes were full-dose attainment, percentage weight change, and dose-response. Adjusted logistic and linear regressions estimated the engagement-persistence and engagement-weight-loss associations. A Baron-Kenny mediation analysis with bootstrap CIs decomposed the engagement-weight-loss association. Missing 48-week weights were imputed using multiple imputation (m=20) as a sensitivity analysis. Among persistent participants who completed all 7 baseline questionnaires (n=91), behavioral-scale associations with weight change were analyzed using Benjamini-Hochberg false-discovery-rate correction.
Results
Of 191 participants (mean age 51.7, SD 6.8 y; 61/191, 31.9% male; mean BMI 45.7, SD 6.8 kg/m²), 37 (19.4%) had never used the platform, 32 (16.8%) used it partially, and 122 (63.9%) fully completed the questionnaires. At 48 weeks, 142 (74.3%) remained on semaglutide, and 124 (87.3%) of them reached the 2.4 mg/week dose. Persistence followed a monotonic gradient across engagement levels (22/37, 59.5%; 23/32, 71.9%; 97/122, 79.5%; P =.02), and each engagement increment was associated with higher odds of persistence (adjusted odds ratio 1.62, 95% CI 1.05‐2.50; P =.03), unchanged under multiple imputation. Mean weight loss was 11.8% (SD 8.4%) in the full cohort and 14.6% (SD 7.3%) among persistent participants, with a steep dose-response (mean 3.9%, SD 5.8% in discontinuers to mean 15.3%, SD 7.2% at 2.4 mg/week; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nutrition-Diabetes Department, Montpellier University Hospital, Centre Hospitalier Universitaire de Montpellier, 191 Avenue Du Doyen Gaston Giraud, Montpellier, 34295, France, 33 467338402.
- Joint Research Unit (UMR) 1302, Desbrest Institute of Epidemiology and Public Health, University of Montpellier, INSERM, Université de Montpellier, Montpellier, France.
- PhyMedExp, INSERM U1046, National Centre for Scientific Research (CNRS) Joint Research Unit (UMR) 9214, University of Montpellier, Université de Montpellier, Montpellier, France.
Zitieren
APA
Tournayre, S., Bonnet, J. B., Anitcheou, J., Faivre, M., Boegner, C., Jalek, A., Jullien, D., Le Rouzic, C., Attalin, V., Myzia, J., Kemba, Y., Sultan, A., & Avignon, A. (2026). Digital Engagement and Predictors of Semaglutide Persistence and Weight Loss in Severe Obesity: 48-Week Observational Study. Journal of Medical Internet Research, 28, e80119-e80119. https://doi.org/10.2196/80119
Vancouver
Tournayre S, Bonnet JB, Anitcheou J, Faivre M, Boegner C, Jalek A, et al. Digital Engagement and Predictors of Semaglutide Persistence and Weight Loss in Severe Obesity: 48-Week Observational Study. Journal of Medical Internet Research. 2026;28:e80119-e80119. doi:10.2196/80119
BibTeX
@article{Tournayre2026,
author = {Tournayre, Sarah and Bonnet, Jean-Baptiste and Anitcheou, Jean and Faivre, Marion and Boegner, Catherine and Jalek, Abdulkader and Jullien, Dominique and Le Rouzic, Camille and Attalin, Vincent and Myzia, Justine and Kemba, Youadigue and Sultan, Ariane and Avignon, Antoine},
title = {Digital Engagement and Predictors of Semaglutide Persistence and Weight Loss in Severe Obesity: 48-Week Observational Study},
journal = {Journal of Medical Internet Research},
year = {2026},
volume = {28},
pages = {e80119--e80119},
doi = {10.2196/80119}
}
EUVIMED